The Atlantic

Readers Discuss Extreme Drug Prices—And What to Do About Them

“The public should receive a cut of any drug profits, just as any other investor might.”
Source: Bryan Woolston / Reuters

Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Many pharmaceutical companies claim that exorbitant drug costs—some companies charge patients $100,000, $200,000, or even $500,000 a year—are necessary to fund expensive research projects that generate new drugs.

But “invoking high research costs to justify high drug prices,” Ezekiel J. Emanuel wrote last week, “is deceptive.” As even some pharmaceutical executives have acknowledged, he said, “there is no necessary link between a decline in drug prices and a decline in R&D.”


Too many people are focused on driving health costs down. It sounds intuitive, but it misses a bigger opportunity: making health costs most effective.

You’re reading a preview, subscribe to read more.

More from The Atlantic

The Atlantic5 min read
The Strangest Job in the World
This is an edition of the Books Briefing, our editors’ weekly guide to the best in books. Sign up for it here. The role of first lady couldn’t be stranger. You attain the position almost by accident, simply by virtue of being married to the president
The Atlantic17 min read
How America Became Addicted to Therapy
A few months ago, as I was absent-mindedly mending a pillow, I thought, I should quit therapy. Then I quickly suppressed the heresy. Among many people I know, therapy is like regular exercise or taking vitamin D: something a sensible person does rout
The Atlantic3 min readAmerican Government
The Strongest Case Against Donald Trump
If Donald Trump beats Nikki Haley on Saturday in her home state of South Carolina, where he leads in the polls, he’s a cinch to win the GOP nomination. And if he wins the GOP nomination, he has a very good shot at winning the presidency. So it’s wort

Related Books & Audiobooks